Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

68%

13 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

13(68.4%)

Phase 1

4(21.1%)

Phase 2

2(10.5%)

19Total

Phase 4(13)

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT06559553Phase 1Recruiting

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

Role: lead

NCT06683885Phase 1Recruiting

A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

Role: lead

NCT06647329Phase 1Not Yet Recruiting

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

Role: lead

NCT04831658Phase 1Unknown

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Role: lead

NCT05274139Phase 2Completed

Treatment of Primary CNS Lymphoma ( FTD )

Role: lead

NCT04490590Phase 4Unknown

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Role: lead

NCT04040491Phase 4Unknown

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Role: lead

NCT04083066Phase 4Unknown

Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma

Role: lead

NCT04038411Phase 4Unknown

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Role: lead

NCT03707847Phase 4Unknown

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Role: lead

NCT03579082Phase 4Unknown

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Role: lead

NCT03558412Phase 4Unknown

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

Role: lead

NCT03513601Phase 4Unknown

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

Role: lead

NCT03107962Phase 2Unknown

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Role: lead

NCT01664975Phase 4Completed

Treatment of Peripheral T-cell Lymphoma

Role: lead

NCT01949818Phase 4Unknown

Treatment of Diffuse Large B Cell Lymphoma

Role: lead

NCT01960192Phase 4Unknown

Treatment of Primary CNS Lymphoma

Role: lead

NCT01501136Phase 4Unknown

Treatment of Natural Killer/T Cell Lymphoma-I/II

Role: lead

NCT01501149Phase 4Unknown

Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ

Role: lead

All 19 trials loaded